Egg Banking Clinical Trial
Official title:
Impact of Egg-Banking in an Ovum-donation Program
Egg-banking would considerably simplify the logistics and means by which oocytes could be donated. These banks would make it easier to immediately provide oocytes that would be compatible to the recipient, shortening or even eliminating the problem of long waiting lists. Egg-banking would also allow the oocytes to be effectively quarantined, drastically diminishing the risk of transmission of infectious diseases in a fashion analogous to semen banks. The most essential prerequisite for a successful egg cryo-banking program is to have an efficient oocyte cryopreservation technology. Recent studies, including our own experience, have indicated that vitrified oocytes preserve intact their potential to fertilize and further develop into competent embryos, giving high clinical results as well as high survival rates. The aim of this study is to evaluate impact of the establishment of an egg-banking in our ovum donation program. Oocyte cryopreservation is carried out by Cryotop method. The study includes oocyte donation cycles conducted with fresh and vitrified oocytes. Recipients are allocated randomly into each group ("fresh vs. vitrified cycles"). Main outcome measures include survival, fertilization, embryo development and clinical outcome.
| Status | Completed |
| Enrollment | 320 |
| Est. completion date | October 2009 |
| Est. primary completion date | September 2009 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 35 Years |
| Eligibility |
Inclusion Criteria: - Receptors - Women receiving donor oocytes and whose partners without seere pathology of semen. - BMI < 25 Donors: Inclusion Criteria: 18 - 35 years oldaños. - Normal Response (8-15 follicles)to long protocol of ovarian stimulation with hCG - Donors with normal menstrual cycles ( 21-35 day duration). - Donors with Body Mass Index (BMI) between 18-25 Kg/m2 Exclusion Criteria: - Donors with +/= two previous miscarriages` - Polycystic Ovary Syndrome - Donors with antecedents of poor embrionary quality not attributed to masculine factor. - Donors with decline of Estradiol Hormone of more than 10% or Estradiol Hormone plateau. - Donors with a high response >20 ovocitos and/or levels above 3000pg/mL of Estradiol the day of the administration of Chorionic gonadotropin (hCG. |
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
| Country | Name | City | State |
|---|---|---|---|
| Spain | Instituto Valenciano de Infertilidad | Valencia |
| Lead Sponsor | Collaborator |
|---|---|
| Instituto Valenciano de Infertilidad, IVI VALENCIA |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To evaluate the clinical outcome in an ovum donation program conducted with egg-banking. | 14 days | No |